Werewolf Therapeutics, Inc. — Director's Dealing 2021

May 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Werewolf Therapeutics, Inc. (HOWL)
CIK: 0001785530
Period of Report: 2020-12-23

Reporting Person: Asanuma Sakae (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-04	Common Stock	C	1318311	—	Acquired	1318311	Indirect
2021-05-04	Common Stock	C	438098	—	Acquired	1756409	Indirect
2021-05-04	Common Stock	P	312500	$16.00	Acquired	2068909	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-23	Series B Preferred Stock	$	P	3797921	Acquired		Common Stock (438098)	Indirect
2021-05-04	Series A Preferred Stock	$	C	11428570	Disposed		Common Stock (1318311)	Indirect
2021-05-04	Series B Preferred Stock	$	C	3797921	Disposed		Common Stock (438098)	Indirect

Footnotes

F1: On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F2: The securities reported herein are held by Taiho Ventures, LLC. Sakae Asanuma is the President & CEO of Taiho Ventures, LLC.

F3: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F4: The Series B Preferred Stock was convertible into common stock on a 8.6691-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.